Un análisis desde la perspectiva del sector de la salud en América Latina y el Caribe
Washington, D.C., 2017
Overview
Rev Panam Salud Publica 40(6), 2016
PLOS Medicine | DOI:10.1371/journal.pmed.1002088 August 23, 2016
Policy Brief
Consolidated Guidelines
Updated 2016
WHO/HIV/2017.05
Research Article
PLOS ONE | https://doi.org/10.1371/journal.pone.0189770 January 2, 2018
May 2018
HIV i-Base
ISSN 1475-2077 www.i-Base.info
Watch for out-of-date information
First questions
You and your doctor Resistance and adherence Treatment choices
htb supplement: 2018 Vol 19:(1)
New drugs in development
July 2018
www.i-Base.info
This progress report reflects achievements made during the first year of implementation (through December 2016), as countries have taken actions in line with new or existing national strategies. The most recent data on country progress in 2016 are based on country-reported data and country-developed... models using Spectrum software that were reported to UNAIDS in 2017.
more
En 2016, en ce début de l’ère des objectifs de développement durable (ODD), la morbidité et la mortalité évitables liées à la grossesse restent inacceptablement élevées. Bien que des progrès substantiels aient été enregistrés, les pays doivent consolider et faire progresser ces acqui...s et élargir leurs objectifs pour aller au-delà de la survie, en visant, pour leurs populations, un niveau de santé et de potentiel optimal.
more
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand...ing access to affordable antiretroviral therapy (ART).
The report is supplemented by 11 drug profiles that contain more detailed information on pricing trends and patent barriers for key antiretroviral drugs and fixed-dose combinations. Also included is an annex of conditions that define eligibility for reduced prices from 15 pharmaceutical companies.
more
Male circumcision reduces a man’s risk of heterosexual acquisition of HIV by about 60%. This guideline provides an evidence-based recommendation on the use of adult male circumcision devices for HIV prevention in public health programmes in high HIV prevalence, resource-limited settings. It also p...resents key programmatic considerations for the introduction and use of these devices in public health HIV prevention programmes. The primary audiences are policy- and decision-makers, programme managers, health-care providers, donors and implementing agencies.
more